

## Industry Evening Mini-Symposium 2017

Monday 11<sup>th</sup> September, 17:30–19:00

Room Blue 1, North Wing, Level +1, MiCo Milano Congressi

# Transitioning clinical data into patient care – recent real-life experiences with Alpha 1

Chaired by Jan Stolk and Berend Stoel

- 17:30–17:35 **Welcome and Introduction**  
*Jan Stolk*
- 17:35–17:50 **Regional lung density and imaging: Latest findings from the RAPID Extension trial**  
*David G. Parr*
- 17:50–18:05 **Clinical implications and challenges for treatment of AATD**  
*Joachim H. Ficker*
- 18:05–18:20 **Going beyond the trials: Strengthening clinical evidence**  
*Charlie Strange*
- 18:20–18:35 **By no means obsolete: Why registry data are important in a rare disease**  
*Jan Stolk*
- 18:35–18:55 **Discussion/Questions**
- 18:55–19:00 **Closing Remarks**  
*Berend Stoel*

Optional dinner provided for health-care professionals after the symposium. Limited seats available. Please sign-up at the welcome desk which will be situated outside the room Blue 1, North Wing, Level +1 at MiCo Milano Congressi from 17:30 onwards

## FACULTY



Jan Stolk is an Associate Professor and Pulmonologist at the Leiden University Medical Center where he specialises in the diagnosis and treatment of patients with Alpha 1 Antitrypsin Deficiency (AATD). He was the principal investigator on several pivotal clinical trials in AATD, in particular the Danish-Dutch trial, which was the first clinical trial to utilise computed tomography to measure the effect of Alpha 1 Antitrypsin on disease progression in AATD.



Berend Stoel is Associate Professor in the Division of Image Processing at Leiden University Medical Centre. His areas of expertise surround the technical and clinical validation of image processing, and its application in the clinical trial setting. He was an investigator for CSL Behring's RAPID programme, providing technical support on the use of computed tomography to quantify emphysema progression in patients with Alpha 1 Antitrypsin Deficiency.



David G. Parr is a Consultant Respiratory Physician and Clinical Director of Cardio-Thoracic services at University Hospital Coventry, and Honorary Professor of Medicine at Warwick University Medical School. His clinical practice concentrates on chronic obstructive pulmonary disease, Alpha 1 Antitrypsin Deficiency, pulmonary vascular disease and interstitial lung disease services at University Hospital Coventry.



Joachim H. Ficker is Chief Physician in the Department of Respiratory Medicine, Allergology, and Sleep Medicine at General Hospital Nuremberg and Head of the Lung and Sleep Medicine Centres in Nuremberg. He was a member of the RAPID Trial Study Group, and an author on the recent RAPID open-label extension trial publication in *Lancet Respiratory Medicine*, concerning the long-term efficacy of Alpha 1 Antitrypsin therapy in Alpha 1 Antitrypsin Deficiency.



Charlie Strange is Professor of Pulmonary and Critical Care Medicine at the Medical University of South Carolina. He is a leading figure in Alpha 1 Antitrypsin Deficiency research and directs the Alpha 1 Foundation Research Registry at the Medical University of South Carolina, which aims to encourage scientific research in this under-recognised condition and to support efforts to improve treatment.